ATE364631T1 - Hauptneutralisationsort des hepatitis e virus und verwendung dieses neutralisationsort in impfungverfahren und in verfahren zum screening nach neutralisationsantikörper - Google Patents
Hauptneutralisationsort des hepatitis e virus und verwendung dieses neutralisationsort in impfungverfahren und in verfahren zum screening nach neutralisationsantikörperInfo
- Publication number
- ATE364631T1 ATE364631T1 AT00982311T AT00982311T ATE364631T1 AT E364631 T1 ATE364631 T1 AT E364631T1 AT 00982311 T AT00982311 T AT 00982311T AT 00982311 T AT00982311 T AT 00982311T AT E364631 T1 ATE364631 T1 AT E364631T1
- Authority
- AT
- Austria
- Prior art keywords
- neutralization
- site
- antibodies
- hepatitis
- virus
- Prior art date
Links
- 238000006386 neutralization reaction Methods 0.000 title abstract 6
- 241000724675 Hepatitis E virus Species 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 4
- 238000012216 screening Methods 0.000 title abstract 2
- 238000002255 vaccination Methods 0.000 title abstract 2
- 230000008569 process Effects 0.000 title 1
- 230000003472 neutralizing effect Effects 0.000 abstract 2
- 241000282577 Pan troglodytes Species 0.000 abstract 1
- 238000012512 characterization method Methods 0.000 abstract 1
- 238000003745 diagnosis Methods 0.000 abstract 1
- 238000002955 isolation Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/28011—Hepeviridae
- C12N2770/28111—Hepevirus, e.g. hepatitis E virus
- C12N2770/28122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16749099P | 1999-12-01 | 1999-12-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE364631T1 true ATE364631T1 (de) | 2007-07-15 |
Family
ID=22607568
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT00982311T ATE364631T1 (de) | 1999-12-01 | 2000-11-30 | Hauptneutralisationsort des hepatitis e virus und verwendung dieses neutralisationsort in impfungverfahren und in verfahren zum screening nach neutralisationsantikörper |
Country Status (6)
Country | Link |
---|---|
US (2) | US6930176B2 (de) |
EP (1) | EP1235862B1 (de) |
AT (1) | ATE364631T1 (de) |
AU (1) | AU1936001A (de) |
DE (1) | DE60035221D1 (de) |
WO (1) | WO2001040270A2 (de) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1274725B1 (de) * | 2000-04-07 | 2006-06-07 | The Government of the United States of America, as represented by The Secretary, Department of Health and Human Services | Verwendung von hev-polypeptiden |
WO2003040341A2 (en) * | 2001-11-07 | 2003-05-15 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Anti-hepatitis a virus antibodies |
JP2005524386A (ja) * | 2001-11-08 | 2005-08-18 | ▲養▼生堂有限公司 | 抗e型肝炎ウイルスモノクローナル抗体、又は結合性を有するそのフラグメント、及びそれらの使用 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2336282T3 (es) * | 1992-09-18 | 2010-04-09 | The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services | Proteinas recombinantes de una cepa paquistani de hepatitis e y su utilizacion en metodos de diagnostico y vacunas. |
US5563032A (en) * | 1992-10-21 | 1996-10-08 | The United States Of America As Represented By The Department Of Health And Human Services | Mosaic polypeptide and methods for detecting the hepatitis E virus |
-
2000
- 2000-11-30 US US10/148,737 patent/US6930176B2/en not_active Expired - Fee Related
- 2000-11-30 WO PCT/US2000/032614 patent/WO2001040270A2/en active IP Right Grant
- 2000-11-30 AU AU19360/01A patent/AU1936001A/en not_active Abandoned
- 2000-11-30 AT AT00982311T patent/ATE364631T1/de not_active IP Right Cessation
- 2000-11-30 DE DE60035221T patent/DE60035221D1/de not_active Expired - Lifetime
- 2000-11-30 EP EP00982311A patent/EP1235862B1/de not_active Expired - Lifetime
-
2005
- 2005-02-09 US US11/054,041 patent/US7148323B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
WO2001040270A2 (en) | 2001-06-07 |
US6930176B2 (en) | 2005-08-16 |
WO2001040270A3 (en) | 2002-01-10 |
US7148323B2 (en) | 2006-12-12 |
DE60035221D1 (de) | 2007-07-26 |
EP1235862A2 (de) | 2002-09-04 |
AU1936001A (en) | 2001-06-12 |
EP1235862B1 (de) | 2007-06-13 |
US20030211463A1 (en) | 2003-11-13 |
US20050233316A1 (en) | 2005-10-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE282429T1 (de) | Immunogene zusammensetzungen gegen den cck-b- gastrin-rezeptor und verfahren zur behandlung von tumoren | |
CY1108765T1 (el) | ΑΓΩΓΗ ME ΑΝΤΙΣΩΜΑΤΑ ANTI-ErbB2 | |
DE60042114D1 (de) | Genomische sequenzen von neisseria und verfahren zu ihrer verwendung | |
MXPA02011656A (es) | Moleculas de acido nucleico nrg-2, polipeptidos, y metodos de diagnostico y terapeuticos. | |
HK1084689A1 (en) | Human anti-ifn-gamma neutralizing antibodies as selective ifn-gamma pathway inhibitors | |
DK1212422T3 (da) | Humane CTLA-4-antistoffer og anvendelserne deraf | |
DE60137631D1 (de) | Ireovirus antikörpern zur behandlung von ras-vermittelten, proliferativen erkrankungen | |
MXPA04003274A (es) | Productos biologicos. | |
DE60223340D1 (de) | Serpin-arzneistoffe zur behandlung einer hiv-infektion und verfahren zu deren verwendung | |
ATE230417T1 (de) | Peptid-immunogene zur schutzimpfung gegen und behandlung von allergien | |
HK1087018A1 (en) | Peptide-based passive immunization therapy for treatment of atherosclerosis | |
DE69939312D1 (de) | Verfahren zur identifizierung von induktoren und inhibitoren proteolytischer antikörper, zusammensetzungen sowie deren verwendungen | |
ATE368110T1 (de) | Zusammensetzung und verfahren zur behandlung von immunverwandten krankheiten | |
ATE415163T1 (de) | Verfahren und zusammensetzungen zur behandlung von augenerkrankungen | |
DE69834578D1 (de) | Verfahren zur behandlung von zementaufschlämmungen | |
ATE364631T1 (de) | Hauptneutralisationsort des hepatitis e virus und verwendung dieses neutralisationsort in impfungverfahren und in verfahren zum screening nach neutralisationsantikörper | |
DE69936994D1 (de) | Verfahren zur behandlung von okularen neovaskularen erkrankungen | |
ATE425187T1 (de) | Materialien und methoden zur behandlung von hepatitis c | |
DE60024997D1 (de) | Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen | |
ATE283920T1 (de) | Verfahren zur immunisierung und behandlung von h. pylori infektion | |
ATE306668T1 (de) | Diagnose von brustkrebs unter verwendung von bcmp-7 als marker | |
DE60144493D1 (de) | Verfahren zur bestimmung und behandlung von tuberöse-sklerose komplex assoziierten erkrankungen | |
ATE408832T1 (de) | Verfahren zum nachweis von blutzell-antigenen und gegen diese gerichtete antikörper | |
WO2004030607A3 (en) | Peptide-based passive immunization therapy for treatment of atherosclerosis | |
ATE307871T1 (de) | Verfahren zur behandlung von gewebe |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |